RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can safely and effectively treat adults with diffuse large B-cell lymphoma that has come back or stopped responding to prior therapy. The drugs work by attaching to cancer cells and e…
Matched conditions: RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 08:22 UTC
-
New combo therapy aims to beat back stubborn lymphoma before stem cell transplant
Disease control Recruiting nowThis study tests a new drug combination (epcoritamab plus chemotherapy) given before a stem cell transplant for people with a type of aggressive lymphoma (DLBCL) that has come back or not responded to prior treatments. The goal is to see if this approach can completely eliminate …
Matched conditions: RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 08:21 UTC
-
New drug may keep lymphoma in check long enough for Life-Saving cell therapy
Disease control Recruiting nowThis study tests a drug called odronextamab given before CAR-T cell therapy in people with large B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this bridging therapy can control the cancer long enough for patients to successfully unde…
Matched conditions: RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 08:15 UTC